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Introduction: Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is 
comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its 
diversity and rarity, developing new therapeutics has been difficult, at best. The standard of care in 
the treatment of advanced and metastatic disease over the last 30 years has been doxorubicin and 
ifosfamide, either alone or in combination. There has been significant focus on developing new thera-
peutics to treat primary and metastatic disease. Trabectedin (ecteinascidin-743) is a tetrahydroiso-
quinoline alkaloid which has been evaluated in the treatment of metastatic soft tissue sarcoma.
Aims: To review the current evidence for the therapeutic use of trabectedin in patients with 
soft tissue sarcoma.
Evidence review: Five phase I studies in patients with solid tumors, all of which include 
sarcoma patients, evaluating the dosing and toxicity of trabectedin were performed with efficacy 
being evaluated as a secondary endpoint. Additionally, there are four phase I trials evaluating 
trabectedin in combination with frontline therapeutic drugs in soft tissue sarcoma. Four phase II 
studies were performed in soft-tissue sarcoma patients with objective response rates ranging 
from 3.7% to 17.1%. Additionally, in two compassionate use trials, objective response rates 
between 14% and 51% were seen, the largest response resulting from a study specifically 
focusing on liposarcoma.
Place in therapy: Trabectedin is a potential therapeutic option for the management of soft-
tissue sarcoma. It appears to have specific activity in a select group of histologies, most notably 
myxoid/round cell liposarcoma. Although it would be helpful to study the use of trabectedin in 
a randomized, controlled fashion, the relative rarity of soft-tissue sarcoma, and heterogeneity 
of the histologic subtypes, makes phase III trials a difficult prospect.
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Core evidence proof of concept summary for trabectedin in soft-tissue sarcoma
Outcome measure Emerging evidence
Efficacy Potential use as monotherapy or combination therapy in patients 
with soft-tissue sarcoma, either as first line therapy or in patients who 
have failed or proven refractory to other cytotoxic chemotherapies.
Response rates Objective response rates ranging from 3.7% to 17.1%, with stable 
disease rates reported to 6 months.
Tolerability Most commonly utilized dose, and maximum tolerated dose 
in several phase i trials is 1.5 mg/m2 as a 24-hour continuous 
intravenous infusion every 21 days, although other shorter infusion 
schedules have been utilized as well.
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Scope, aims, and objectives
Adult soft tissue sarcomas (STS) are a heterogeneous group 
of malignant tumors arising from the embryonal mesen-
chymal tissue layers which account for less than 1% of all 
malignant neoplasms. There are approximately 10,000 new 
STSs diagnosed every year in the United States and over 47% 
percent of those patients will die from their disease.
Only two anticancer treatments to date, doxorubicin and 
ifosfamide, have consistently shown single-agent activity 
in this heterogeneous disease group with responses in the 
10%–20% range as single agents and up to 40% in combination. 
Trabectedin, formerly known as ecteinascidin-743 (ET-743), 
is a natural marine compound derived from the Caribbean 
tunicate Ecteinascidia turbinata. Trabectedin is currently 
approved for the treatment of STS in Europe but has not yet 
been approved in the United States. The objective of this article 
is to present an overview of current therapeutic options in STS 
and to review the current evidence for the therapeutic potential 
of trabectedin in this disease group.
Methods
A literature search was conducted on January 4, 2009 in the 
following databases using the search terms ‘trabectedin’, 
‘ET-743’, or ‘Yondelis® and sarcoma’. The cut-off date was 
from the beginning of the database to the date of the search 
unless otherwise stated. Searches were completed in PubMed 
from 1966 to date, search strategy ‘trabectedin and sarcoma’ 
limited to English language results only; in EMBASE from 
1970 to date, search strategy ‘trabectedin and sarcoma’ 
limited to English and human studies.
A total of 57 records were identified in PubMed. Records 
were manually reviewed and any animal studies, in vitro 
studies, case studies, general narrative reviews, and articles 
focusing on other entities which mentioned trabectedin were 
excluded. The remaining 13 records were included.
A total of 112 records were identified in EMBASE. 
Records were manually reviewed and again, any animal 
studies, in vitro studies, case studies, general narrative 
reviews, and articles focusing on other entities which 
mentioned trabectedin were excluded. Any articles which 
were included in the PubMed data search were excluded. 
The remaining four records were included.
The identified studies were then classified into five classes 
of evidence based on the design of the study, with level 1 
evidence presenting the strongest evidence and level five 
representing the weakest evidence, as indicated in Table 1. 
No systematic reviews or meta-analyses were identified. 
Publications relating to the pharmacoeconomic evidence of 
trabectedin were not identified.
Disease overview
Approximately 10,000 new cases of STS are diagnosed annu-
ally in the United States,1 and fewer than 50% of patients 
will receive curative treatment with the currently available 
treatment modalities. Accounting for approximately 1% 
of all adult malignancies, STS comprise a heterogeneous 
group of malignancies that arise from the connective tissues. 
While sarcomas can arise virtually anywhere, the most 
common primary site is the extremities. This is followed by 
the retroperitoneum, torso, and head and neck.2 There are 
over 50 different subtypes of STS, and the World Health 
Organization (WHO) classifies most STS according to the 
presumptive tissue of origin.3 This, along with the overall 
rarity of the disease, account for the difficulty in conducting 
large randomized clinical trials.
STS tend to metastasize early via a hematogenous route, 
with a predilection for the lungs and less frequently the liver 
and bone. Lymphangitic spread is uncommon (3%), except 
for certain histologic types such as rhabdomyosarcomas, 
epithelioid sarcomas, and angiosarcomas.4,5 About 10% of 
patients present with metastatic disease, and although the 
majority of patients will present with a clinically localized 
tumor, 30%–60% will eventually develop a local recurrence 
or metastatic disease.6,7 This percentage increases up to 70% 
for patients with high-grade STS.8
Analysis of the distribution of primary histology and 
grade demonstrates that among patients that develop lung 
metastases, leiomyosarcoma (LMS) is most common, 
followed by undifferentiated pleomorphic high grade 
sarcoma, liposarcoma, and synovial sarcoma. The incidence 
(Continued)
Outcome measure Emerging evidence
Safety Generally, well tolerated with noncumulative, reversible, and manageable 
adverse events including neutropenia, nausea and vomiting, and elevated 
transaminases. rhabdomyolysis and acute renal failure were observed 
in a few notable cases.Core Evidence 2009:4 193
Trabectedin in soft tissue sarcoma Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of pulmonary metastases within each histologic group 
correlates with the incidence of high-grade lesions within 
that group.9
The development of metastatic disease poses a major 
clinical problem as it is seldom amenable to a curative 
treatment. The efficacy of conventional chemotherapy is 
limited with response rates of 10%–40% for single agent or 
combination therapy.10,11
Current therapy options
Surgical resection with wide margins, with or without 
radiation therapy, remains the standard of care for localized 
disease with continued debate when deciding upon the use of 
adjuvant chemotherapeutic treatment options.12 Doxorubicin 
and ifosfamide have been used both as single agents and 
as combination therapy and remains the mainstay of treat-
ment in most histologies of STS. Recently, gemcitabine and 
docetaxel have proven efficacious in the treatment of LMS 
and undifferentiated pleomorphic high grade sarcoma, and 
have been increasingly used as a first line regimen in these 
histologic subtypes.11 Investigators have evaluated the use of 
pegylated liposomal doxorubicin (PLD) in several phase II 
clinical trials, trying to capture the efficacy of doxorubicin 
while minimizing the side effects like cardiac toxicity and 
myelosuppression.13,14 The results of the studies evaluating 
PLD have never matched those of its parent drug, but with 
a safer side effect profile, in certain circumstances, it is 
preferable. The taxanes, along with PLD, have been spe-
cifically evaluated in angiosarcomas, and are often used as 
first-line drugs in this particular histologic subtype.15
Given the relative rarity of STS, along with the het-
erogeneity of the sarcoma subtypes, it has been difficult 
to perform meaningful studies to evaluate drug efficacy. 
A retrospective study performed by the European Orga-
nization for Research and Treatment of Cancer (EORTC) 
soft tissue and bone sarcoma group demonstrated that only 
8% of patients with advanced or metastatic disease treated 
with a doxorubicin-based regimen are alive at five years.8 
Furthermore, the toxicity encountered with the use of 
doxorubicin and/or high-dose ifosfamide, often times lim-
its their use as palliative chemotherapeutic options, which 
unfortunately is what is often needed most in the advanced 
disease setting.
Trabectedin (Yondelis®, Pharma Mar, Madrid, Spain), 
was originally a natural product derived from the Caribbean 
marine tunicate Ecteinascidia turbinata. The current supply 
is based on a semi-synthetic process.16 It is a tetrahydroiso-
quinoline alkaloid that binds to the minor groove of DNA 
and selectively inhibits DNA transcription17 and assembly 
of the microtubular cytoskeleton.17,18 At the cellular level, 
trabectedin blocks cell cycle progression in the G2/M 
phase through a p-53-independent apoptotic process which 
effectively inhibits transcriptional activation of inducible 
genes.19
Clinical evidence for the use  
of trabectedin in the treatment of STS
Phase i studies of trabectedin  
as a single agent
Phase I studies have evaluated a variety of dosing schedules. 
A phase I trial and compassionate use trial used a 24-hour 
continuous infusion schedule in 29 pretreated, advanced 
soft-tissue sarcomas and bone sarcomas. The study demon-
strated disease response in fibrosarcoma, liposarcoma and 
osteosarcoma, with a recommended dose of 1.5 mg/m2.20,21 
A phase I pharmacokinetic trial using the same infusion 
schedule in patients with solid tumors enrolled 14 sarcoma 
patients, in which nine were treated at the recommended dose. 
Two of the partial disease responses in this trial included 
an osteosarcoma and a liposarcoma patient.21 A phase I and 
pharmacokinetic study of trabectedin was performed in 
children with refractory tumors in a Children’s Oncology 
Group study. Twelve evaluable patients were followed to 
establish a pediatric dose with a recommended phase II dose 
of 1.1 mg/m2 administered as a 3 hour IV infusion. One child 
with Ewing’s sarcoma experienced a complete response. This 
patient had complete resolution of pulmonary metastases and 
remained on therapy for a total of 16 courses. The most com-
mon toxicity was reversible hepatic toxicity which occurred 
in 58% of patients.22 A phase I and pharmacokinetic study 
was performed using a one- or three-hour intravenous (IV) 
infusion every 21 days in patients with solid tumors in a total 
of 72 patients, including three gastrointestinal stromal tumor 
patients and three uterine sarcomas. Forty-nine patients were 
evaluable for tumor response at the end of the trial (68%) 
with two objective tumor responses (one complete response 
[CR] and one partial response [PR]), both observed in the 
three-hour infusion cohort. Both objective responses were 
in sarcoma patients, the first, a uterine LMS patient who 
received 10 cycles of trabectedin at a dose of 1.5 mg/m2 and 
had a CR of 18 weeks duration. The PR was observed in a 
stromal sarcoma of the colon, who received 17 cycles of 
treatment and after cycle 13, had a PR of six months duration. 
A third patient with gastric stromal sarcoma, who did not 
meet RECIST criteria for PR, achieved a 37% reduction Core Evidence 2009:4 194
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in tumor size and stable disease for 20 weeks. The most 
frequently encountered non-hematologic toxicities were 
nausea, vomiting, fatigue and increased liver transaminases. 
Grade 3 and 4 neutropenia and thrombocytopenia were 
observed at the highest dose level with the one-hour infusion 
and at the 1.3 mg/m2 dose level with the three-hour infusion.23 
A daily five day schedule was evaluated in a phase I study 
that included 42 patients. Three patients on this study had 
discernable antitumor activity, one of which was a uterine 
LMS patient, who experienced a 41% reduction in lung 
metastases and a 27% overall tumor response after four 
courses of 325 µg/m2/day.24
Combination phase i studies 
of trabectedin
Several phase I studies in solid tumor patients including 
sarcoma patients were performed with trabectedin, in 
combination with other cytotoxic chemotherapies, with the 
idea of expanding on the encouraging sarcoma responses 
seen in the earlier phase I single-agent studies. These studies 
were also prompted by in vitro studies showing synergy 
between trabectedin and cisplatin and trabectedin and 
doxorubicin, specifically in STS cells.17,25 The most obvious 
STS combination is trabectedin in combination with 
doxorubicin. In a phase I, open-label study conducted at 
five sites evaluating 41 patients with soft-tissue sarcoma, 
doxorubicin was administered as a fifteen minute infu-
sion in doses ranging from 50–75 mg/m2 followed by 
trabectedin in doses ranging from 0.9 mg/m2 to 1.3 g/m2 
as a three-hour IV infusion. The maximum tolerated 
dose (MTD) in this study given in three week cycles was 
trabectedin 1.1 mg/m2 with doxorubicin 60 mg/m2 with 
granulocyte-colony stimulating factor (G-CSF) support 
given significant myelosuppression. Although the primary 
goal of this study was not tumor response, as in the other 
phase I studies, there were partial responses (PR) observed in 
5/41 patients (21%) and stable disease (SD) in 34/41 patients 
(83%).26 Another phase I study evaluating the same duo of 
drugs evaluated 38 previously untreated STS and breast 
cancer patients with a dose of 60 mg/m2 of doxorubicin and 
trabectedin in doses escalating from 600 µg/m2 to 800 µg/m2 
which was the MTD due to febrile neutropenia. Ten patients 
in this study achieved a PR, five with STS and five with breast 
cancer. The sarcoma histologies that responded were LMS, 
liposarcoma, carcinosarcoma, uterine adenosarcoma and 
malignant schwannoma. Toxicity was similar to that seen in 
the other phase I studies with severe but reversible hepatic 
toxicity, nausea and vomiting and fatigue. Noncumulative 
neutropenia occurred in all patients with the nadir occurring 
around day 15 and taking seven days to recover.17 A variation 
on the anthracycline theme was a phase I study combining 
pegylated liposomal doxorubicin (PLD) with trabectedin. 
In an open label study, 36 assessable patients, 16 of which 
were sarcoma (44%) were treated with 30 mg/m2 of PLD and 
trabectedin infused over three hours at doses ranging from 
0.4 mg/m2 to 1.3 mg/m2 repeated every 21 days. The MTD 
was 1.1 mg/m2 with similar elevations in transaminases and 
myelosuppression that had been seen in other phase I trials. 
Interestingly, fifteen patients on the trial achieved cumula-
tive anthracycline doses of 300 mg/m2 (two with previous 
exposure). Repeated multiple gated acquisition scans or 
two-dimensional (2D) echocardiograms revealed decreased 
cardiac ejection fractions (left ventricular ejection fraction 
[LVEF]  20% versus baseline) in six patients. As per the 
protocol, five of six patients continued on with trabectedin 
alone, and at the end of study, three patients had improve-
ment in ejection fraction, and the other three did not have 
available studies to review. The overall response rate for the 
sarcoma patients was 12.5% with an additional six sarcoma 
patients (37.5%) achieving disease stabilization. The histo-
logic subtypes of the sarcoma patients were not mentioned 
in the published study results.27 Lastly, in a phase I trial 
of weekly trabectedin with gemcitabine in patients with 
advanced solid tumors, 15 patients received gemcitabine 
on days 1, 8, and 15 of a 28-day schedule followed by 
trabectedin with doses ranging between 0.3 mg/m2 and 
0.58 mg/m2. Five patients in this study had STS. The study 
was terminated early due to an unacceptable frequency of 
adjustments to the weekly dosing schedule due to hepatic 
toxicity. There were no dose-limiting toxicities observed and 
Table 1 Evidence base included in the review
Category Number of records
Full papers Abstracts
initial search 112 0
records excluded 97 0
records included 14 1
Level 1 evidence 0 0
Level 2 evidence (rCT) 0 0
Level  3 14 1
Trials other than rCT
Pharmacokinetic studies
Pharmacodynamic studies
Economic evidence 0 0
Abbreviation: rCT, randomized, controlled trial.Core Evidence 2009:4 195
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no objective responses, although almost half of the patients 
(47%) analyzed had stable disease after two cycles.28
The phase ii clinical experience  
in soft tissue sarcoma
A total of 225 assessable patients were evaluated in four 
phase II clinical trials evaluating the efficacy of trabectedin 
in soft-tissue, gastrointestinal stromal tumor (GIST) and bone 
sarcoma patients. The largest of these studies was a multicenter, 
nonrandomized EORTC study evaluating one hundred and 
four patients with soft tissue and bone sarcoma from eight 
European institutions. Patients were stratified to three major 
disease groups; non-GIST patients with prior chemotherapy 
evaluated by WHO criteria, non-GIST patients without prior 
chemotherapy evaluated by WHO criteria and RECIST 
criteria, and GIST patients without prior therapy evaluated 
by WHO criteria. The GIST patients will be commented on 
below. Trabectedin was administered at a dose of 1.5 mg/m2 
IV as a 24-hour continuous infusion every three weeks. 
The most commonly encountered side effects and toxicities 
were similar to those experienced in the phase I trials: nausea, 
vomiting, myelosuppression, and rise in liver transaminases. 
Forty-three patients (41%) had LMS of various locations, 
17.3% had synovial sarcoma, 9.6% with liposarcoma, and 
5.7% with “MFH”. Ninety percent of patients had grade 2 or 
3 sarcomas. Among the 99 treated patients, there were eight 
PR (objective regression rate of 8.1%), 45 no change (40.5%), 
and 39 with progressive disease (39.4%). The median duration 
of response was 352 days (50 weeks). The responses were 
seen in LMS, synovial, liposarcoma, and MFH. The outcome 
was similar in patients who had received one or two previous 
chemotherapy lines and in patients having chemosensitive or 
chemoresistant sarcoma.29 The third group evaluated in the 
above trial, but reported separately were the GIST patients 
without any prior therapy. Twenty-eight patients with locally 
advanced and/or metastatic GIST with progressive disease 
were enrolled onto the EORTC study. No objective responses 
were seen, and 67% of patients experienced progressive 
disease after their first evaluation, while 33% experienced no 
change as their best response. This portion of the study was 
performed prior to the imatinib era for GIST, and the studies 
conclusion was that trabectedin could be added to the long list 
of ineffective drugs for GIST.30
Another phase II and pharmacokinetic study of tra-
bectedin was performed in patients with STS refractory 
to chemotherapy. Thirty-six patients were enrolled on this 
study at three institutions, and again, the 1.5 mg/m2 24-hour 
infusion schedule was utilized. Objective responses were 
seen in three patients, with one complete response in a 
myxoid/round-cell liposarcoma patient and two partial 
responses, one in a dedifferentiated liposarcoma patient and 
the other in a LMS patient. These responses were durable for 
up to 20 months. Two minor responses were also seen with 
43% and 47% tumor reduction, for an overall clinical benefit 
rate of 14% in two patients, one with a myxoid/round-cell 
liposarcoma and one with a fibrosarcoma.31
Additionally, a phase II study of trabectedin in advanced 
pretreated STS patients treated at four separate French insti-
tutions utilizing the 1.5 mg/m2 24-hour infusion schedule 
every three weeks was performed. Two distinct groups 
were evaluated, one group had prior therapy with one or two 
single agents or one combination therapy, and the second 
group had prior therapy with three or more single agents or 
two or more combination therapies. Fifty-four patients were 
enrolled and all were assessable for efficacy. Two partial 
responses were seen (3.7%) and four patients had minor 
responses (7.4%). Furthermore, nine patients had stable 
disease for 6 months (17%). Four of the responding patients 
had LMS, three of which were uterine, one patient had 
a uterine endometrial stromal sarcoma, and one patient had a 
head and neck fibrosarcoma. Of note, there were two deaths 
on this trial that were possibly attributable to trabectedin. Both 
patients developed acute renal failure with febrile neutropenia 
and rhabdomyolisis, although there was note of a protocol 
violation that may have led to the fatal outcome.21
Lastly, 36 chemotherapy-naïve patients were enrolled on a 
phase II trial utilizing the 24-hour continuous infusion schedule 
every 21 days. The predominant histologic subtype was LMS 
and liposarcoma and tumor bulk was 5 cm in two thirds of 
patients and 10 cm in 19% of patients. Approximately half 
of the patients had received prior radiation therapy, but only 
11% had received prior chemotherapy. Six of the 35 assessable 
patients exhibited an objective response of 17.1%. The 
responses, similar to other studies, occurred in myxoid/round 
cell sarcoma (three patients), LMS (one patient), fibrosarcoma 
(one patient), and synovial sarcoma (one patient). As expected, 
the most severe toxicities were primarily hematologic and 
hepatic. Although the study sample size was small, the out-
come of this phase II trial concluded that trabectedin induced 
responses in 17% of study patients with a one year overall 
survival rate of 72%.32 These results rivaled those from other 
first-line studies using doxorubicin and ifosfamide.33–35
Compassionate use trials
There are two studies published to date that evaluated a 
total of 72 patients in compassionate use trials. The first Core Evidence 2009:4 196
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study focused specifically on liposarcoma, given this 
histologic subtype responses seen in the other phase II trials. 
Fifty-one patients with advanced myxoid liposarcoma treated 
at five separate institutions in a compassionate use program 
were retrospectively reviewed. The drug was given either as 
a 24-hour continuous infusion or as the three-hour infusion 
every 21 days. RECIST criteria were utilized and after a 
median follow up of 14 months, two patients had achieved 
complete responses and 24 patients had partial responses 
providing an overall response rate of 51%. The second study 
evaluated 21 patients at a single UK center, also treated on a 
compassionate use basis. All the patients had received prior 
anthracycline and 95% had received ifosfamide. Partial 
responses were seen in three patients (14%) and a further 
eight patients (38%) achieved a durable stable disease for a 
median of 4.5 months. The responses were seen in a liposar-
coma patient, a Ewing’s sarcoma patient, and STS NOS.
resource utilization
Trabectedin met approval in July of 2007 by the Committee 
for Medicinal Products for Human Use in Europe. The 
European Commission has authorized its use and it is com-
mercially available in several countries in Europe and Japan 
where it is marketed for the treatment of STS in adults after 
failure of standard therapy. The approval dose is 1.5 mg/m2 
as a 24-hour continuous infusion, once every three weeks. 
Pharma Mar, who markets trabectedin in Europe and Japan 
has started a phase III multicenter study of Yondelis® as first 
line therapy in patients with tumor translocation sarcomas. 
Trabectedin is currently not commercially available in the 
United States and Canada. It is currently available in several 
expanded access studies focusing on patients with persistent 
or recurrent STS who have exhausted other therapeutic 
options. Ortho Biotech Products, LP a subsidiary of Johnson 
& Johnson will market trabectedin in North America. 
A registration dossier was submitted to the FDA in late 2008 
for the treatment of refractory ovarian cancer and a decision 
of approval is expected to take place in 2009.
Dosage, administration, 
and formulations
The recommended dose, as it is approved in Europe, 
is 1.5 mg/m2 body surface area, administered as an 
IV infusion over 24 hours with a three week interval 
between cycles. Administration through a central venous 
catheter is suggested. All patients should receive 20 mg of 
dexamethasone intravenously 30 minutes prior to trabectedin, 
not only as an anti-emetic, but also as a liver protectant. 
Additional anti-emetics can be administered as needed. Oral 
pre-medication with dexamethasone administered 24 hours 
prior to trabectedin therapy, dramatically reduced myelosup-
pression and hepatotoxciity.36,37
Although grade 3 and 4 nausea and vomiting were 
observed in some patients, many of the well-known and 
debilitating side effects associated with doxorubicin and 
ifosfamide, were not observed, namely, cardiac and neuro-
toxicity.37
Unopened vials have a shelf life of 36 months. After 
reconstitution, chemical and physical stability has been dem-
onstrated for 30 hours up to 25 °C. No incompatibilities have 
been observed between trabectedin and polyvinylchloride 
and polyethylene bags and tubing, and titanium implantable 
access systems.38
Safety and toxicity
As with other cytotoxic chemotherapeutics, the side effect 
profile can be extensive. Reversible myelosuppression was 
found to be one of the most common grade 3 and 4 toxicities 
in the phase I and II studies. This suppression appears to be 
dose dependent, with median nadir at approximately 14 days. 
Trabectedin neutropenia seems to be largely dependent on 
the intensity of the dose, but not the duration of infusion.39 
Reversible increases in serum transaminases, bilirubin and 
alkaline phosphatase were also observed. The elevation gen-
erally took place 2–5 days after trabectedin administration, 
reaching a maximum level between days 5–9. With the 
addition of dexamethasone, there is a hepatic protective 
effect as evaluated in a semi mechanistic pharmacokinetic/
pharmacodynamic model by Fetterly et al.40 Dexamethasone 
can also aid in the prevention of nausea and vomiting.
Place in therapy
The current best available evidence from several non-
randomized phase II trials, coupled with the compelling expe-
rience from several phase I studies suggest that trabectedin is 
a safe and effective therapeutic option in STS with specific 
efficacy in myxoid/round cell sarcoma, and LMS (Table 2). 
In a disease group as diverse as sarcoma, complicated by the 
lack of good therapeutic options in the second line setting, 
trabectedin has limited but compelling evidence to support its 
use in patients who have exhausted other therapeutic options. 
It remains to be seen if trabectedin will be approved in the US, 
either for ovarian cancer, or for STS. The small non random-
ized studies that have been performed thus far have shown that 
trabectedin is clearly not a home run when it comes to most 
STS subtypes; however, in isolated subsets of patients, like Core Evidence 2009:4 197
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myxoid/round cell liposarcoma, there is compelling evidence 
to suggest it is a viable treatment option. As compelling as 
this information is, evaluating this data in a randomized, 
prospective fashion, will substantiate this claim. As the finish-
ing touches are being put on this article, trabectedin is being 
approved in Italy, and should be available to Italian sarcoma 
patients in the ensuing weeks. This adds Italy, to the roster of 
other countries, including Russia, where trabectedin, under 
the trade name Yondelis®, is available. Perhaps the phase 
III study, which will evaluate the safety and effectiveness 
of trabectedin versus doxorubicin-based chemotherapy in 
patients with translocation-related sarcomas, will provide 
sufficient evidence for the US Food and Drug Administration 
to approve this drug in soft-tissue sarcoma for those patients 
who have exhausted other therapeutic options.
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